newsfilter
← Latest News
Business Wire·

Intersect ENT Receives CE Mark Approval for PROPEL® Contour for Patients with Chronic Rhinosinusitis Following Frontal Sinus Surgery

Localized steroid-releasing sinus implant designed to maintain sinus opening now available in select EU countries Intersect ENT®, Inc. (NASDAQ:XENT), a global ear, nose and throat ("ENT") medical technology leader dedicated to transforming patient c